Key Highlights

  • Shares are indicated up 14.81% to $5.66 in pre-market trading, against a prior close of $4.93.
  • The company received FDA 510(k) clearance for TriNav Advance, a new addition to its Pressure-Enabled Drug Delivery portfolio.
  • The device expands access to smaller, distal blood vessels for liver embolization procedures, using a compatible microcatheter.
  • The clearance brings the company's total FDA-cleared device count to three.
  • A limited market release of the new device is planned for the coming weeks.
  • Market Capitalization stands at roughly $303.56 million.

A New Device Clearance Broadens the Liver Therapy Portfolio

TriSalus Life Sciences (NASDAQ:TLSI) shares are indicated sharply higher in pre-market trading after the company announced it has received FDA clearance for TriNav Advance, the newest addition to its drug delivery device lineup.

The Westminster, Colorado-based company is an oncology-focused medical technology Business developing devices and an investigational immunotherapy to treat patients with difficult-to-treat liver and pancreatic tumors. Its Pressure-Enabled Drug Delivery approach is designed to modulate pressure and flow during treatment so that more therapy reaches a tumor while reducing exposure to surrounding healthy tissue, a mechanism now supported by a third FDA-cleared device on the company's platform. With TriNav Advance, the company says it now offers a complete portfolio addressing liver-directed therapy cases, with the new device's indication also supporting a broader range of embolization procedures beyond the liver.

The New Device Reaches Vessels Earlier Tools Could Not

TriNav Advance is built to work in two distinct configurations depending on a patient's anatomy and treatment goals. In its telescoping configuration, the device pairs with a separate, compatible microcatheter, with its SmartValve positioned proximal to the delivery site, allowing physicians to selectively reach small, distal blood vessels that were harder to access with the company's earlier devices, while preserving the pressure-based delivery approach the platform is built around. In its high-flow configuration, it can be used on its own like a standard infusion device, without the added microcatheter, for straightforward infusion through a larger vessel. Because liver embolization cases vary widely in vessel size and structure, giving physicians that flexibility to choose between two approaches in a single device platform may extend the company's reach into procedures it previously could not fully support, particularly those involving more difficult, tortuous vessel anatomy.

A Third Cleared Device Rounds Out the Platform

The clearance brings the company's total FDA-cleared device count to three, joining its existing infusion systems for liver and pancreatic tumors that already use the same underlying pressure-based delivery technology. Rounding out the device portfolio this way is also relevant to the company's broader pipeline, since it continues to investigate its lead immunotherapy candidate, an experimental compound designed to work alongside these delivery devices to address the immune-suppressing environment that tumors can create in the liver.

Commercial Rollout Will Take Time

A limited market release of TriNav Advance is planned over the coming weeks rather than an immediate, full-scale launch. That measured rollout approach means today's regulatory milestone is likely to translate into commercial Revenue only gradually, giving physicians time to adopt the new device across a broader set of procedures before any meaningful contribution shows up in the company's financial results.